Alnylam Pharma (ALNY) Reports In-Line Q3 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Alnylam Pharma (ALNY), Medicines Co. (MDCO) Announce Positive Data from Ongoing ALN-PCSsc Phase 1
November 11, 2015 10:47 AM ESTAlnylam Pharma (NASDAQ: ALNY) and The Medicines Company (Nasdaq: MDCO) reported positive results from their ongoing Phase 1 clinical trial with ALN-PCSsc in a late-breaking oral presentation at the American Heart Association (AHA) Scientific Sessions 2015.
ALN-PCSsc is an investigational RNAi therapeutic... More
Medicines (MDCO)/Alnylam (ALNY) to Present Phase 1 Data on siRNA-based PCSK9 Today
November 11, 2015 8:23 AM ESTEvercore ISI analyst Umer Raffat notes Medicines Co. (NASDAQ: MDCO)/Alnylam Pharma (NASDAQ: ALNY) will present updated Ph 1 data on their siRNA-based PCSK9 at AHA late breaker today/
Below are key things Raffat is... More
